Want to see YTENQ full AI Analyst Report?
Top Page
Yield10 Bioscience
(OTC:YTENQ)
Select Model
Select Model
Rating:23Underperform
Price Target:―
Action:N/A
Date:12/13/24
Yield10 Bioscience's overall score reflects severe financial distress, weak technical indicators, poor valuation, and negative market reaction to recent earnings. These factors indicate a high-risk profile with substantial challenges ahead.
Positive Factors
Proprietary Technology
Yield10's proprietary technology in seed trait development provides a competitive edge in enhancing crop productivity, crucial for long-term growth in the agricultural bioscience sector.
Negative Factors
Financial Distress
Ongoing financial distress, marked by high leverage and negative cash flows, poses significant risks to operational stability and future growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Technology
Yield10's proprietary technology in seed trait development provides a competitive edge in enhancing crop productivity, crucial for long-term growth in the agricultural bioscience sector.
Read all positive factors
Yield10 Bioscience (YTENQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$69.00
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)76.78
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees29
SectorBasic Materials
Sector Strength58
IndustryAgriculture
Share Statistics
EPS (TTM)N/A
Shares Outstanding692,683
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Yield10 Bioscience Business Overview & Revenue Model
Company Description
Yield10 Bioscience, Inc. is an agricultural bioscience company, which focuses on the development of technologies to produce step-change improvements in crop yield for food and feed crops to enhance global food security. The company was founded by ...
How the Company Makes Money
Yield10 Bioscience generates revenue through collaborations and research agreements with agricultural and biotechnology companies interested in leveraging its advanced trait development technologies. The company sells licenses to its proprietary s...
Yield10 Bioscience Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | ― | ― | ― | ― | ― |
| Gross Profit | 60.00K | -7.30M | 6.82M | 6.16M | -4.04M |
| EBITDA | -14.16M | -13.15M | -11.47M | -9.43M | -13.01M |
| Net Income | -14.46M | -13.57M | -11.03M | -10.21M | -12.96M |
Balance Sheet | |||||
| Total Assets | 3.91M | 8.09M | 20.41M | 14.52M | 16.72M |
| Cash, Cash Equivalents and Short-Term Investments | ― | ― | ― | ― | ― |
| Total Debt | 3.18M | 2.65M | 3.17M | 3.62M | 4.22M |
| Total Liabilities | 6.39M | 3.69M | 4.39M | 4.99M | 5.83M |
| Stockholders Equity | ― | ― | ― | ― | ― |
Cash Flow | |||||
| Free Cash Flow | -10.11M | -11.56M | -9.44M | -8.72M | -8.71M |
| Operating Cash Flow | -10.07M | -11.40M | -9.25M | -8.66M | -8.65M |
| Investing Cash Flow | ― | ― | ― | ― | ― |
| Financing Cash Flow | ― | ― | ― | ― | ― |
Yield10 Bioscience Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.03
Negative
0.39
Negative
Market Momentum
>-0.01
Negative
28.42
Positive
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YTENQ, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.39, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 28.42 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for YTENQ.
Yield10 Bioscience Risk Analysis
Yield10 Bioscience disclosed 43 risk factors in its most recent earnings report. Yield10 Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Yield10 Bioscience Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
45 Neutral | $12.27M | -1.14 | 79.78% | ― | -25.50% | -905.27% | |
45 Neutral | $4.69M | -0.65 | -80.73% | ― | 13.43% | 75.01% | |
43 Neutral | $65.20M | -1.19 | -27.83% | 1.36% | -3.54% | 56.67% | |
34 Underperform | $26.96M | -0.11 | -154.24% | ― | -31.20% | -796.06% | |
23 Underperform | $69.00 | ― | ― | ― | ― | ― |
* Basic Materials Sector Average
YTENQ
Yield10 Bioscience
―
―
―
AVD
American Vanguard
2.23
-3.37
-60.18%
SEED
Origin Agritech
1.05
0.00
0.00%
SNES
SenesTech
0.89
-4.09
-82.05%
BIOX
Bioceres Crop Solutions
0.42
-1.67
-79.81%
BGLC
BioNexus Gene Lab Corp
1.48
-2.82
-65.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.